BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
Who’s Going to BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
473 companies and 473 speakers at BIO-Europe 2026, a ~5,800-person, almost entirely industry partnering meeting of European biotech and pharma dealmakers and investors. As of Nov 10, 2026.
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Merck KGaA Darmstadt, Germany | ◆Platinum Sponsor |
Science and technology company active in healthcare, life science and electronics; operates as EMD Serono and MilliporeSigma in North America. | Talk Mon Nov 9 09:00–10:00 Building Your BD Career: What Really Moves the Needle What it takes to build a career in drug licensing and partnership deals, from scientific and financial skills to credibility and contacts. Talk Mon Nov 9 15:00–16:15 Merck's EMEA Advance Biotech Grant Program Five young biotech companies pitch their science to Merck, competing for a grant that helps them bring a product to market. Panel Mon Nov 9 13:00–13:45 Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery. Panel Tue Nov 10 14:00–14:45 Immunology under the microscope: New frontiers What is new in drugs for autoimmune and inflammatory diseases: emerging targets, recent trial results, and where companies are investing and partnering. Talk Tue Nov 10 09:15–09:30 Pharma Presentation: Merck Merck's three businesses: medicines for diseases such as multiple sclerosis and cancer, tools for scientists, and technology for electronics. Panel Tue Nov 10 16:00–16:45 Unlocking Clinical Trial Systems How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely. Panel Wed Nov 11 09:00–09:45 From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance. |
Bayer Leverkusen, Germany | ◆Platinum Sponsor |
Life sciences company with pharmaceuticals, consumer health and crop science divisions. | Talk Tue Nov 10 09:00–09:30 An Outlook into the Year 2050: Navigating the Future of Efficiency and Innovation How AI, global expansion and patient community outreach may reshape the way clinical trials are run, and what to change now to prepare. Panel Tue Nov 10 15:00–15:25 Inside the Incubator: What It Really Takes to Build a Biotech Company Today What incubators backed by big drug companies look for in young biotechs, and how they help founders with money, advice and partners. Panel Tue Nov 10 16:30–16:55 The Role of Innovation in Biopharma Growth How new ideas and technologies drive growth for drug companies, and how to keep innovating while scaling up, with real examples. Panel Wed Nov 11 10:00–10:45 AI Regulations: Driving Innovation While Navigating Compliance What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation. Panel Wed Nov 11 11:00–12:00 Collaborative Innovation in CDMO Partnerships How drug companies and contract manufacturers develop new therapies together, with examples of what makes these partnerships work and where they struggle. |
Boehringer Ingelheim Ingelheim am Rhein, Germany | ◆Platinum Sponsor |
Family-owned pharmaceutical company developing human and animal health medicines. | Panel Mon Nov 9 13:00–13:45 Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery. Talk Tue Nov 10 13:00–14:00 Biologics Manufacturing Excellence How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently. Talk Tue Nov 10 09:30–09:45 Pharma Presentation: Boehringer Ingelheim Boehringer Ingelheim, independent since 1885, and its research on human and animal medicines for diseases that lack good treatments. Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. Panel Wed Nov 11 10:00–10:45 Most Favoured Nations: A Game-Changer for Biotech Dealmaker? How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans. |
European Medicines Agency Amsterdam, Netherlands | |
EU agency that evaluates and supervises medicines for human and veterinary use. | Panel Mon Nov 9 11:15–12:00 Unlocking Pharma’s Productivity Potential Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive. Business of Biotech Panel Tue Nov 10 13:00–13:45 Aligning with Regulators to Propel Innovation What help and incentives the European Medicines Agency offers developers of new treatments, and how to use them on the road to approval. Panel Tue Nov 10 14:00–14:45 Harnessing Regulatory Sandboxes to Drive Innovation in Novel Therapeutics & Technologies How regulatory sandboxes, where regulators let new products be tested under adjusted rules, could support new therapies and health technologies in Europe. Panel Wed Nov 11 10:00–10:45 AI Regulations: Driving Innovation While Navigating Compliance What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation. Panel Wed Nov 11 09:00–09:45 From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance. |
Informa London, United Kingdom | |
Events, publishing and data group that runs BIO-Europe and publishes BioXconomy. | Keynote Mon Nov 9 10:15–10:30 Talk Mon Nov 9 09:30–10:00 partneringONE essentials workshop Newcomers learn what to expect from partnering meetings, including timing and etiquette, and how to get the most from the partneringONE system. Panel Tue Nov 10 09:00–09:45 Networks or neurons: What’s next in CNS dealmaking? What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop. Talk Tue Nov 10 11:30–12:00 partneringONE power up workshop Experienced delegates learn advanced partneringONE features and team habits that save time and raise how often their meeting requests are accepted. Panel Wed Nov 11 13:00–13:45 BIO-Europe Media Round-Up: The Stories Shaping Biopharma Right Now Journalists pick out the biggest biopharma news stories and deal trends of the moment and explain what they mean for dealmakers. Panel Wed Nov 11 09:00–09:45 How is the APAC region reshaping global biopharma? How China, Japan, South Korea and other Asia-Pacific countries are moving from making drugs to inventing them, and how Western firms can partner. |
Biogen Cambridge, Massachusetts | ◆Platinum Sponsor |
Develops and markets therapies for neurological and neurodegenerative diseases, including multiple sclerosis and Alzheimer's disease. | Talk Mon Nov 9 09:00–10:00 Build, Buy, or Partner? Choosing Your Market Entry Strategy How drug companies choose between licensing a new product to a regional partner, selling it themselves, or both, with lessons from each path. Business of Biotech Panel Mon Nov 9 13:00–14:00 Navigating partnering and business development in a shifting global landscape How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples. Panel Tue Nov 10 16:00–16:45 AI and Innovation in Clinical Trials: Transforming Operations and Accelerating Development How AI can speed clinical trials, from drafting trial plans and finding patients to computer-simulated patients that cut how many real ones are needed. Panel Tue Nov 10 15:00–15:45 Mastering the Shifting Regulatory Landscape: Leveraging the Biotech Act for Innovation and Global Success How the EU Biotech Act aims to restore Europe's edge through faster trial approvals, quicker rare disease access and proportionate oversight of advanced therapies. |
Johnson & Johnson New Brunswick, NJ | ◆Platinum Sponsor · Johnson & Johnson Innovation |
Healthcare company developing innovative medicines and medical technologies; its Innovation unit partners with external researchers and start-ups. | Panel Mon Nov 9 16:15–17:00 Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work? What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies. Panel Tue Nov 10 10:00–10:25 Regulatory Updates for Orphan and Pediatric Medicines How updated EU drug laws change the rewards for rare-disease and children's medicines, such as longer protection from competing copies. Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. Panel Wed Nov 11 12:00–12:45 What's Next for Biomanufacturing Strategies? Where the manufacturing of biological medicines is heading, from sturdier supply chains and industry mergers to AI and new ways to scale up. |
Novo Nordisk Bagsværd, Denmark | ◆Gold Sponsor |
Danish pharmaceutical company, branded Novo since September 2026, making medicines for diabetes, obesity and rare diseases. | Panel Mon Nov 9 11:15–12:00 Unlocking Pharma’s Productivity Potential Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive. Business of Biotech Panel Tue Nov 10 15:30–15:55 Accelerating Innovation: Creating the Right Environment for Success in Biopharma Partnerships How to design partnerships that work, from payments tied to research milestones and shared risk to guarding intellectual property while sharing ideas. Panel Tue Nov 10 10:00–10:45 Cardiometabolic innovations beyond GLP-1 – Where are we now? Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going. Panel Tue Nov 10 15:00–15:45 Longevity – Are we getting younger? What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape. |
Find buyers from companies at BIO-Europe 2026
Tell us what you sell and we’ll find the people at these companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
When and where was BIO-Europe 2026?
BIO-Europe 2026 ran November 9–11, 2026, at Koelnmesse in Cologne, Germany.
What conference is this?
BIO-Europe is an annual European biotech partnering conference, held November 9–11, 2026 at Koelnmesse in Cologne. Most of its value is in pre-arranged one-to-one partnering meetings between biotech and pharma business-development teams and investors; the program adds panels and talks on the business of biotech, ecosystem innovation, therapeutics, biomanufacturing, clinical and regulatory strategy.
What is in this guide?
Every organization we can place at BIO-Europe 2026: 473 speakers from the public speaker list and agenda (206 sessions) rolled up to their companies and institutions, plus the 127 sponsors, delegations and supporters from the public sponsor list with their tier — 473 organizations in one list. Speakers appear as job titles, never by name. The partnering attendee list needs a login and is not included. A company presentation appears with its time slot once the organizers name the presenting company on the agenda; a presenter whose slot is not named yet is listed with their organization.
How are organizations typed?
By the role an organization plays at a partnering meeting: drug developers (large pharma and biotech), investors, the service providers around them — CDMOs and CROs, tools, data and AI companies, consulting, legal and other services — and academic, government and association bodies, including national and regional delegations. The track filters come from the track an organization speaks in.
How current is it?
Pulled from the public agenda, speaker list and sponsor list on November 10, 2026, while the meeting was under way.
Browse BIO-Europe 2026 by
Organizations with their own page
395 organizations — every exhibitor, every company with talks or known attendees, and every organization with 2 or more presentations.
- 3billion
- 3DBioFibR
- 59 North Communications
- A-Alpha Bio
- A2 Healthcare
- AAVantgarde Bio
- AB Cube
- AbbVie
- AbbVie Contract Manufacturing
- Ability Biotherapeutics
- Acadia Pharmaceuticals
- Aerska
- AGC Biologics
- Agilex Biolabs
- Agomab Therapeutics
- aimed analytics
- AinB
- Alia Therapeutics
- Alithia Life Sciences
- Alkeus Pharmaceuticals
- Alliance for mRNA Medicines
- Allinky Biopharma
- Almirall
- AlphaSense
- Alphyn Biologics
- ALTx Therapeutics
- Andera Partners
- AndzonBio2
- Angelini Ventures
- AOP Health
- Apikal Therapeutics
- argenx
- Artelo Biosciences
- Asabys Partners
- AseBio
- Asgard Therapeutics
- Astellas
- AstraZeneca
- ATB Antivirals
- ATHOS
- Atlanpole Biotherapies
- ATLATL Ventures
- Atrogi
- AusBiotech
- Australia
- Avecho Biotechnology
- Avenue Biosciences
- AviadoBio
- Avid Bioservices
- Avion CRO
- Azitra
- Basecamp Research
- Basque Health Cluster
- Bayer
- BEAM Alliance
- Beijing Huawei Medicines
- Bellberry
- BeNatureBioLab
- BeOne Medicines
- BIO Deutschland
- BIO.NRW
- BIO4 Campus
- Biocant
- Biocat
- BioCina
- Biocytogen
- Biogen
- Biogenera
- BioIndustry Association
- BioM
- biomindz
- Bionow
- BioNTech
- BioPartner UK
- BIOPRO Baden-Württemberg
- Bioqube Ventures
- BIORCHESTRA
- BioRiver
- BioRN
- biosaxony
- BioSpace
- BIOTECanada
- Biotechnology Innovation Organization (BIO)
- BioUK
- BIOVAL
- Biovance Capital
- Biovia
- BioWin
- BioXconomy
- Blackstone Life Sciences
- Blue Earth Therapeutics
- Blue Matter Consulting
- BNP Paribas Asset Management
- Boehringer Ingelheim
- Bold Therapeutics
- Boston Scientific
- Bough Biosciences
- Brenus Pharma
- Bristol Myers Squibb
- Business Finland
- Business Region Göteborg
- Business Turku
- BVIZ
- CAGE Bio
- Camarco
- Cancer Trials Australia
- CARBio Therapeutics
- Caregen
- CD4 Therapeutics
- Cellistic
- CellNBetter
- Cellula Therapeutics
- Cellweaverse
- Celonic
- Cereno Scientific
- Chiesi
- Chrysea
- Chugai Pharmaceutical
- Citeline
- Claret Capital Partners
- Claris Ventures
- Clarivate
- Clinmark
- CMAX Clinical Research
- Columbus Venture Partners
- Concr
- Constellate Proteomics
- ConvEyXO
- Copenhagen Capacity
- Corteria Pharmaceuticals
- CPHI Middle East & BIO Middle East
- Crux Biolabs
- CSL Behring
- CuraCell
- Debiopharm
- Deep Intelligent Pharma
- Dentons
- Dermagnostix
- Divamics
- Earlybird Venture Capital
- Eir Ventures
- Eleva
- Eli Lilly
- Elpiscience
- Elutiq
- EMICRO Biomedicine
- endogene.bio
- Enosis Santé
- Epitopea
- EQT Life Sciences
- ESC Advisors
- EUCOPE
- European Biotechnology Magazine
- European Commission
- European Innovation Council
- European Investment Bank
- European Medicines Agency
- Evaluate
- EVERSANA
- eversyn
- EVerZom
- EVOLUTION Life Science Partners
- Evotec
- Ewopharma
- Exogenus Therapeutics
- FGK Clinical Research
- FindMeCure
- Finnish Bioindustries
- Flagship Pioneering
- Flanders Investment & Trade
- Forbion
- Form Bio
- FoRx Therapeutics
- FRESCI
- Gedeon Richter
- GenAIz
- Genmab
- Genrix Biopharmaceutical
- German Centers for Health Research (DZG)
- Germany Trade & Invest
- GlioCART
- Global Victoria
- good healthcare pharma
- Government of Canada
- Government of Navarra
- Government of Ontario
- Government of South Australia
- Graythan Regulatory Services
- Greenwich LifeSciences
- GSK
- Guangzhou Innogen Pharmaceutical
- Haixi Pharmaceuticals
- Handelsblatt
- Hansa Biopharma
- Harmonix
- HealthCap
- HealthCare Royalty
- High-Tech Gründerfonds
- HollandBIO
- HTW Berlin
- Huonslab
- IamFluidics
- Idorsia
- IDT Biologika
- IGES Institut
- Immatics
- ImmunoKey
- Infinite Biotech
- Inflant
- Informa
- Ingenix
- Innovation Agency Lithuania
- Inovis
- Insilico Medicine
- Insmed
- Inveready
- Invest in Skåne
- Invest Ontario
- Investissement Québec
- iPark Institute
- Ipsen
- IsomAb
- Italian Trade Agency
- Japan Bioindustry Association
- Jeito Capital
- JETRO
- Johnson & Johnson
- Just – Evotec Biologics
- Kantify
- KBI Biopharma
- Korea Health Industry Development Institute
- Krystal Biotech
- Kurma Partners
- leap:up
- Legend Biotech
- Life Science Austria
- Life Science Nord
- Life Sciences BC
- LifeArc
- LinkGevity
- Longevity.Technology
- Lonza
- Luna Therapeutics
- Lundbeck
- M Ventures
- MabDesign
- MaH Clinical Trial Solutions
- Mallia Innovations
- MEDiC Life Sciences
- Medicon Valley Alliance
- Medicxi
- Medidata
- MediWales
- Megalab
- Melodia Therapeutics
- Merck KGaA
- Micro CRISPR
- Miltenyi Biomedicine
- MitoRx Therapeutics
- Monument Tx
- MRM Health
- MSD
- MSQ Ventures
- Mustbio
- MVRIX
- nagene
- Navarra Health Cluster
- Navira Bio
- NEC Bio
- Neohla Bio
- NextCell Pharma
- NK Bioscience
- NMD Pharma
- Norstella
- Novartis
- Novo Holdings
- Novo Nordisk
- NovoArc
- Novotech
- OBIO
- OKG Capital
- ONA Therapeutics
- One Nucleus
- OPIS
- Optimapharm
- Optimovo
- Optimum Communications
- OrbiMed
- Orbis Medicines
- Orvida Pharma
- Osborne Clarke
- Oslo Cancer Cluster
- Otsuka
- OvartiX
- Ovid Therapeutics
- Oxford BioTherapeutics
- Parexel
- Pathios Therapeutics
- Pavonis Diagnostics
- Pfizer
- Phaeosynt
- Phinomics
- Pin Therapeutics
- Pioneer Group
- Porton Pharma Solutions
- Portrai
- PostEra
- Prague.bio
- Pregene
- ProBioGen
- Procavea Biotech
- Progeneer
- Protagonist Therapeutics
- Prudentia Sciences
- PTC Therapeutics
- Pullan Consulting
- R Kupiec Consulting
- Regeneron
- Remora Biotech
- Rentschler Biopharma
- Resolution Therapeutics
- Restora Neurosciences
- Rezon Bio
- RNATICS
- Roche
- Roche Venture Fund
- Romulus Therapeutics
- Ropes & Gray
- Samsung Biologics
- SanBio
- Sandoz
- Sanofi
- Sartorius
- Scientia Clinical Research
- Scitaris
- SeNostic
- Seroba
- Servier
- SILREAL
- Sinovoy Health Group
- Siteworks
- Slingshot Therapeutics
- Sofinnova Partners
- Sound Bioventures
- SPRIND
- SRTD Biotech
- Stand Up Therapeutics
- Star Tree Ventures
- Stemmatters
- Strategic Transactions Advisory
- Studia
- Superbranche
- Surginex
- Sustained Therapeutics
- SwedenBIO
- Swiss Biotech Association
- SWISS Orphan EDC
- Syncona
- Syneos Health
- Synergya
- Taiwan Bio Industry Organization
- Thuja Capital
- TissUse
- Tiziana Life Sciences
- TLC BioSciences
- Topia Life Science
- Toursynbio
- Trade and Invest British Columbia
- Transcenta
- TransPerfect
- TrialHub
- Tubulis
- TVM Capital Life Science
- Txinno Bioscience
- UCB
- Uniphar
- Uute Scientific
- V-Bio Ventures
- ValiRx
- Valneva
- VARIANT
- Vasthera
- Venture Valuation
- VeonGen Therapeutics
- Viacure
- Vicore Pharma
- Vivet Therapeutics
- Wallonia Export & Investment Agency (AWEX)
- WinHealth Pharma
- Women's Health Fund
- WuXi AppTec
- WuXi Biologics
- XGEN Venture
- Yatrex Pharmaceuticals
- Ymmunobio
Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction